[A19-12] Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 15.08.2019
Project no.:
A19-12
Commission:
Commission awarded on 04.02.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Treatment-naive adults with intermediate/poor-risk advanced renal cell carcinoma
Indication of considerable added benefit for intermediate risk profile; indication of major added benefit for poor risk profile
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A13-44 | Ipilimumab (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A18-44 | Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-12 | Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-54 | Nivolumab (renal cell carcinoma) - Addendum to Commissions A19-11 and A19-12 | Commission completed |
| A12-07 | Ipilimumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A20-116 | Ipilimumab (non-small cell lung cancer, combination with nivolumab) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-08-15 A G-BA decision was published.